Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12897446 | 0.89 | — | — | |
| SCHEMBL21645205 | 0.86 | PLA2G1B (0.39) | PLA2G1BATG4BGAAHPGDKMT2A | |
| SCHEMBL27171915 | 0.84 | PLA2G1B (0.38) | PLA2G1BATG4BGAAHPGDKMT2A | |
| SCHEMBL20745368 | 0.84 | PLA2G1B (0.38) | PLA2G1BATG4BGAAHPGDKMT2A | |
| SCHEMBL20497839 | 0.84 | PLA2G1B (0.38) | PLA2G1BATG4BGAAHPGDKMT2A | |
| SCHEMBL6522699 | 0.84 | PLA2G1B (0.38) | PLA2G1BATG4BGAAHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL20498322 | 0.83 | PLA2G1B (0.37) | PLA2G1BATG4BGAAHPGDKMT2A | |
| Hydrochloric Acid SCHEMBL20499156 | 0.83 | PLA2G1B (0.37) | PLA2G1BATG4BGAAHPGDKMT2A | |
| SCHEMBL15154826 | 0.81 | GAA (0.48) | PLA2G1BATG4BGAAHPGDKMT2A | |
| SCHEMBL16653833 | 0.81 | EPHX2 (0.42) | PLA2G1BATG4BGAAHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | claimed |
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC | 2009-07-23 | — | — | US | claimed |
| CN-101448820-A | Piperidinyl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | claimed |
| EP-2032554-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-11 | — | — | EP | claimed |
| CN-101119717-A | Substituted phenols as agents inhibiting VEGF production | PTC THERAPEUTICS INC (US) | 2008-02-06 | — | — | CN | claimed |
| WO-2007137955-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | claimed |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2007-12-06 | — | — | US | claimed |
| EP-4727591-A1 | SMARCA2 DEGRADERS AND USES THEREOF | Astrazeneca AB (SE) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024256988-A1 | SMARCA2 DEGRADERS AND USES THEREOF | ASTRAZENECA AB (SE) | 2024-12-19 | — | — | WO | disclosed |
| CN-117813295-A | Compounds targeting p53 mutants | 北京加科思新药研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-105646331-A | Piperidine compounds, pharmaceutical composition comprising the same and its use | 爱思开生物制药株式会社 | 2016-06-08 | — | — | CN | disclosed |
| US-8426441-B2 | Inhibitors of bruton's tyrosine kinase | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| CN-101952283-B | Imidazo [1,2-a ] pyridine and imidazo [1,2-b ] pyridazine derivatives | HOFFMANN LA ROCHE | 2013-04-17 | — | — | CN | disclosed |
| WO-2009077334-A1 | NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| CN-101448820-A | Piperidinyl pyrimidine derivatives | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | disclosed |
| EP-2032554-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| CN-101119717-A | Substituted phenols as agents inhibiting VEGF production | PTC THERAPEUTICS INC (US) | 2008-02-06 | — | — | CN | disclosed |
| WO-2007137955-A1 | PIPERIDINYL PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-06 | — | — | WO | disclosed |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HOFFMAN-LA ROCHE INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186898-A1 | Inhibitors of bruton's tyrosine kinase | BTK, SYK, LYN | PLA2G1B 2345/4885ATG4B 4781/4885GAA 2507/4885 |
| US-20070281921-A1 | Piperidinyl pyrimidine derivatives | HRH2, P2RX5, P2RX3 | PLA2G1B 1491/4885ATG4B 2975/4885GAA 992/4885 |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | VEGFA, FLT4, FLT1 | PLA2G1B 3063/4885ATG4B 543/4885GAA 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.